{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "bromocriptine",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Take bromocriptine mesylate capsules orally with food ( 2.2 ) Recommended dosage for hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Increase the dosage up to 2.5 mg once daily every two to seven days within a recommended dosage of 2.5 mg to 15 mg once daily ( 2.3 ) Recommended dosage for prolactin-secreting adenomas is 1.25 mg to 2.5 mg once daily.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Increase the dosage within a recommended dosage of 2.5 mg to 10 mg once daily ( 2.4 ) Recommended dosage for acromegaly is 1.25 mg to 2.5 mg once at bedtime for 3 days.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Before initiating bromocriptine mesylate capsules, evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer bromocriptine mesylate ( 2.1 ). Take bromocriptine mesylate capsules orally with food ( 2.2 ) Recommended dosage for hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Increase the bromocriptine mesylate dosage up to 2.5 mg once daily every two to seven days as tolerated until an optimal therapeutic response is achieved within a recommended dosage of 2.5 mg to 15 mg once daily.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "( 5.1 ) Pleural, Pulmonary and Retroperitoneal Fibrosis: During bromocriptine mesylate treatment monitor for signs and symptoms of progressive fibrosis, (e.g., pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular obstruction).",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the loin/flank, lower limb edema, abdominal masses or tenderness that may indicate retroperitoneal fibrosis).",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for bromocriptine (Bromocriptine mesylate), retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary Pregnancy in Patients with Hyperprolactinemia-Associated Dysfunction and Prolactin-Secreting Adenomas: In patients being treated with bromocriptine mesylate capsules for hyperprolactinemia, bromocriptine mesylate should generally be withdrawn when pregnancy is diagnosed.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "If bromocriptine mesylate is continued or reinstituted in select patients to manage a prolactin-secreting macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate capsules should be weighed against the possible risk of its use during a hypertensive disorder of pregnancy.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Pregnancy in Patients with Acromegaly : In patients being treated with bromocriptine mesylate for acromegaly who subsequently become pregnant, a decision should be made as to whether bromocriptine mesylate continues to be medically necessary or can be withdrawn.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "Pregnancy: See the Full Prescribing Information regarding the recommendations for using bromocriptine mesylate during pregnancy ( 8.1 ) Lactation: Avoid the use of bromocriptine mesylate during lactation in postpartum females.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "Postpartum Period: Avoid use of bromocriptine mesylate capsules for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions ( 5.4 )] .",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      },
      {
        "text": "No teratological or embryotoxic effects of bromocriptine were produced in any of six offspring from six monkeys at a bromocriptine dose level of 2 mg/kg. 8.2 Lactation Risk Summary Avoid the use of bromocriptine mesylate capsules during lactation in postpartum females.",
        "source": "US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/bromocriptine.json",
        "verbatim": true
      }
    ]
  }
}